Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis
of Target-specific Nanotherapies in Disease Models

Christina      Tran; Eden      Park; Pedro   L. Rodriguez   Flores; Robert   B.   Campbell
doi:10.2174/1574885517666220426092902
Abstract

Extensive studies have explored potential therapies against multiple myeloma (MM), whether in hospitals, universities, or in private institutional settings. Scientists continue to study the mechanism(s) underlying the disease as a basis for the development of more effective treatment options. There are many therapeutic agents and treatment regimens used for multiple myeloma. Unfortunately, no cure or definitive treatment options exist. The goal of treatment is to maintain the patient in remission for as long as possible. Therapeutic agents used in combination can effectively maintain patients in remission. While these therapies have increased patient survival, a significant number of patients relapse. The off-target toxicity and resistance exhibited by target cells remain a challenge for existing approaches. Ongoing efforts to understand the biology of the disease offer the greatest chance to improve therapeutic options. Nanoparticles (targeted drug delivery systems) offer new hope and directions for therapy. This review summarizes FDA-approved agents for the treatment of MM, highlights the clinical barriers to treatment, including adverse side effects normally associated with the use of conventional agents, and describes how nanotherapeutics have overcome barriers to impede conventional treatments.
Keywords: Cancer therapy, drug resistance, nanotechnology, multiple myeloma, nanomedicine, liposomes.
« Previous Next »
Graphical Abstract

[1]
Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med  2004; 351(18): 1860-73.
[http://dx.doi.org/10.1056/NEJMra041875] [PMID:  15509819] 
[2]
Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin  2014; 64(6): 422-44.
[http://dx.doi.org/10.3322/caac.21252] [PMID:  25266555] 
[3]
Zaidi AA, Vesole DH. Multiple myeloma: An old disease with new hope for the future. CA Cancer J Clin  2001; 51(5): 273-85.
[http://dx.doi.org/10.3322/canjclin.51.5.273] [PMID:  11577492] 
[4]
Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood  1989; 73(4): 865-79.
[http://dx.doi.org/10.1182/blood.V73.4.865.865] [PMID:  2465790] 
[5]
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol  2005; 23(15): 3412-20.
[http://dx.doi.org/10.1200/JCO.2005.04.242] [PMID:  15809451] 
[6]
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med  2011; 364(11): 1046-60.
[http://dx.doi.org/10.1056/NEJMra1011442] [PMID:  21410373] 
[7]
Altekruse SFKC, Krapcho M, Neyman N, et al. SEER cancer statistics review, 1975-2007. National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/csr/1975_2007/

[8]
Howlader NNA, Krapcho M, Miller D, et al. SEER cancer statistics review, 1975-2017. National Cancer Institute. Bethesda, MD. Available from https://seer.cancer.gov/csr/1975_2017/

[9]
Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood  2003; 101(3): 1128-40.
[http://dx.doi.org/10.1182/blood-2002-06-1737] [PMID:  12393520] 
[10]
Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol  2012; 9(3): 135-43.
[http://dx.doi.org/10.1038/nrclinonc.2012.15] [PMID:  22349016] 
[11]
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A Report From International Myeloma Working Group. J Clin Oncol  2015; 33(26): 2863-9.
[http://dx.doi.org/10.1200/JCO.2015.61.2267] [PMID:  26240224] 
[12]
de la Puente P, Azab AK. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. Eur J Haematol  2017; 98(6): 529-41.
[http://dx.doi.org/10.1111/ejh.12870] [PMID:  28208215] 
[13]
Zheleznyak A, Shokeen M, Achilefu S. Nanotherapeutics for multiple myeloma. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2018; 10(6): e1526.
[http://dx.doi.org/10.1002/wnan.1526] [PMID:  29701006] 
[14]
Campbell RB. Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem  2006; 6(6): 503-12.
[http://dx.doi.org/10.2174/187152006778699077] [PMID:  17100555] 
[15]
Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci  2009; 98(2): 411-29.
[http://dx.doi.org/10.1002/jps.21458] [PMID:  18563780] 
[16]
Gultepe E, Reynoso FJ, Jhaveri A, et al. Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution. Nanomedicine (Lond)  2010; 5(8): 1173-82.
[http://dx.doi.org/10.2217/nnm.10.84] 
[17]
Li Z, Li X, Cao Z, et al. Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model. Oncol Rep  2012; 27(4): 1035-40.
[http://dx.doi.org/10.3892/or.2012.1635] [PMID:  22245938] 
[18]
Kuesters GM, Campbell RB. Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine (Lond)  2010; 5(2): 181-92.
[http://dx.doi.org/10.2217/nnm.09.105] [PMID:  20148631] 
[19]
Swami A, Reagan MR, Basto P, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci USA  2014; 111(28): 10287-92.
[http://dx.doi.org/10.1073/pnas.1401337111] [PMID:  24982170] 
[20]
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science  2010; 327(5971): 1345-50.
[http://dx.doi.org/10.1126/science.1177319] [PMID:  20223979] 
[21]
Davies F, Baz R. Lenalidomide mode of action: Linking bench and clinical findings. Blood Rev  2010; 24 (Suppl. 1): S13-9.
[http://dx.doi.org/10.1016/S0268-960X(10)70004-7] [PMID:  21126632] 
[22]
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood  2000; 96(9): 2943-50.
[http://dx.doi.org/10.1182/blood.V96.9.2943] [PMID:  11049970] 
[23]
Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood  2003; 101(4): 1530-4.
[http://dx.doi.org/10.1182/blood-2002-08-2543] [PMID:  12393500] 
[24]
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood  2012; 120(14): 2817-25.
[http://dx.doi.org/10.1182/blood-2012-05-425934] [PMID:  22833546] 
[25]
Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res  2014; 20(17): 4574-83.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0695] [PMID:  24987056] 
[26]
de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol  2011; 186(3): 1840-8.
[http://dx.doi.org/10.4049/jimmunol.1003032] [PMID:  21187443] 
[27]
Fancher KM, Bunk EJ. Elotuzumab: The first monoclonal antibody for the treatment of multiple myeloma. J Adv Pract Oncol  2016; 7(5): 542-7.
[PMID:  29282429] 
[28]
Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol  2012; 30(16): 1953-9.
[http://dx.doi.org/10.1200/JCO.2011.37.2649] [PMID:  22547589] 
[29]
Richardson PG, Lee HC, Abdallah AO, et al. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J  2020; 10(10): 106.
[http://dx.doi.org/10.1038/s41408-020-00369-0] [PMID:  33097687] 
[30]
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol  2020; 21(2): 207-21.
[http://dx.doi.org/10.1016/S1470-2045(19)30788-0] [PMID:  31859245] 
[31]
Rajkumar SV, Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc  2016; 91(1): 101-19.
[http://dx.doi.org/10.1016/j.mayocp.2015.11.007] [PMID:  26763514] 
[32]
Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood  2019; 134(16): 1337-45.
[http://dx.doi.org/10.1182/blood.2019000241] [PMID:  31484647] 
[33]
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet  2017; 389(10068): 519-27.
[http://dx.doi.org/10.1016/S0140-6736(16)31594-X] [PMID:  28017406] 
[34]
Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med  2014; 371(10): 906-17.
[http://dx.doi.org/10.1056/NEJMoa1402551] [PMID:  25184863] 
[35]
Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood  1998; 92(9): 3131-6.
[http://dx.doi.org/10.1182/blood.V92.9.3131] [PMID:  9787148] 
[36]
Eom KS, Min CK, Lee S, et al. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. Jpn J Clin Oncol  2006; 36(7): 432-8.
[http://dx.doi.org/10.1093/jjco/hyl041] [PMID:  16782727] 
[37]
Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood  1997; 89(3): 789-93.
[http://dx.doi.org/10.1182/blood.V89.3.789] [PMID:  9028309] 
[38]
Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med  2012; 366(19): 1782-91.
[http://dx.doi.org/10.1056/NEJMoa1114138] [PMID:  22571202] 
[39]
Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre, randomised, open-label, phase 3 study. Lancet Haematol  2020; 7(6): e456-68.
[http://dx.doi.org/10.1016/S2352-3026(20)30099-5] [PMID:  32359506] 
[40]
Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol  2012; 30(24): 2946-55.
[http://dx.doi.org/10.1200/JCO.2011.39.6820] [PMID:  22802322] 
[41]
Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med  2012; 366(19): 1759-69.
[http://dx.doi.org/10.1056/NEJMoa1112704] [PMID:  22571200] 
[42]
Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol  2010; 11(1): 29-37.
[http://dx.doi.org/10.1016/S1470-2045(09)70284-0] [PMID:  19853510] 
[43]
Gertz MA, Lacy MQ, Inwards DJ, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant  1999; 23(3): 221-6.
[http://dx.doi.org/10.1038/sj.bmt.1701559] [PMID:  10084252] 
[44]
Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia  2008; 22(7): 1419-27.
[http://dx.doi.org/10.1038/leu.2008.99] [PMID:  18432260] 
[45]
Ferlay J. Cancer incidence, mortality and prevalence worldwide GLOBOCAN2002  2004.

[46]
Girnius S, Munshi NC. Challenges in multiple myeloma diagnosis and treatment. Leuk Suppl  2013; 2(S1) (Suppl. 1): S3-9.
[http://dx.doi.org/10.1038/leusup.2013.2] [PMID:  27175259] 
[47]
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc  2003; 78(1): 21-33.
[http://dx.doi.org/10.4065/78.1.21] [PMID:  12528874] 
[48]
Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia  2012; 26(1): 149-57.
[http://dx.doi.org/10.1038/leu.2011.196] [PMID:  21799510] 
[49]
Shaughnessy JD Jr, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood  2011; 118(13): 3512-24.
[http://dx.doi.org/10.1182/blood-2010-12-328252] [PMID:  21628408] 
[50]
Buda G, Ricci D, Huang CC, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol  2010; 89(11): 1133-40.
[http://dx.doi.org/10.1007/s00277-010-0992-3] [PMID:  20532504] 
[51]
Nojima M, Maruyama R, Yasui H, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res  2009; 15(13): 4356-64.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-3336] [PMID:  19549772] 
[52]
Ciechanover A. Intracellular protein degradation: From a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). Angew Chem Int Ed  2005; 44(37): 5944-67.
[http://dx.doi.org/10.1002/anie.200501428] [PMID:  16142822] 
[53]
Karki R, Pandya D, Elston RC, Ferlini C. Defining “mutation” and “polymorphism” in the era of personal genomics. BMC Med Genomics  2015; 8(1): 37.
[http://dx.doi.org/10.1186/s12920-015-0115-z] [PMID:  26173390] 
[54]
Türk D, Szakács G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel  2009; 12(2): 246-52.
[PMID:  19333870] 
[55]
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica  2016; 101(4): 396-406.
[http://dx.doi.org/10.3324/haematol.2015.129189] [PMID:  27033237] 
[56]
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis  2010; 31(1): 27-36.
[http://dx.doi.org/10.1093/carcin/bgp220] [PMID:  19752007] 
[57]
Llinàs-Arias P, Esteller M. Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: An update. Open Biol  2017; 7(9): 170152.
[http://dx.doi.org/10.1098/rsob.170152] [PMID:  28931650] 
[58]
Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy  2006; 26(7): 1018-22.
[http://dx.doi.org/10.1592/phco.26.7.1018] [PMID:  16803426] 
[59]
Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood  2010; 116(23): 4745-53.
[http://dx.doi.org/10.1182/blood-2010-07-294983] [PMID:  20807892] 
[60]
Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol  2004; 126(5): 715-21.
[http://dx.doi.org/10.1111/j.1365-2141.2004.05078.x] [PMID:  15327525] 
[61]
Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia  2008; 22(2): 414-23.
[http://dx.doi.org/10.1038/sj.leu.2405062] [PMID:  18094721] 
[62]
Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol  2009; 146(2): 164-70.
[http://dx.doi.org/10.1111/j.1365-2141.2009.07728.x] [PMID:  19545290] 
[63]
Ashley JD, Quinlan CJ, Schroeder VA, et al. Dual carfilzomib and doxorubicin-loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma. Mol Cancer Ther  2016; 15(7): 1452-9.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0867] [PMID:  27196779] 
[64]
Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev  2013; 65(1): 36-48.
[http://dx.doi.org/10.1016/j.addr.2012.09.037] [PMID:  23036225] 
[65]
Duggan ST, Keating GM. Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs  2011; 71(18): 2531-58.
[http://dx.doi.org/10.2165/11207510-000000000-00000] [PMID:  22141391] 
[66]
Wu D, Zhu L, Li Y, et al. Chitosan-based colloidal polyelectrolyte complexes for drug delivery: A review. Carbohydr Polym  2020; 238: 116126.
[http://dx.doi.org/10.1016/j.carbpol.2020.116126] [PMID:  32299572] 
[67]
Chandy T, Sharma CP. Chitosan-as a biomaterial. Biomater Artif Cells Artif Organs  1990; 18(1): 1-24.
[http://dx.doi.org/10.3109/10731199009117286] [PMID:  2185854] 
[68]
Lall A, Kamdem Tamo A, Doench I, et al. Nanoparticles and colloidal hydrogels of chitosan–caseinate polyelectrolyte complexes for drug-controlled release applications. Int J Mol Sci  2020; 21(16): 5602.
[http://dx.doi.org/10.3390/ijms21165602] [PMID:  32764340] 
[69]
Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res  2002; 19(10): 1389-99.
[http://dx.doi.org/10.1023/A:1020427227285] [PMID:  12425455] 
[70]
Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther  2006; 112(3): 630-48.
[http://dx.doi.org/10.1016/j.pharmthera.2006.05.006] [PMID:  16815554] 
[71]
Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res  2002; 93(10): 1145-53.
[http://dx.doi.org/10.1111/j.1349-7006.2002.tb01217.x] [PMID:  12417045] 
[72]
Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos  2013; 41(1): 230-7.
[http://dx.doi.org/10.1124/dmd.112.047662] [PMID:  23118326] 
[73]
Ao L, Reichel D, Hu D, et al. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. J Pharmacol Exp Ther  2015; 355(2): 168-73.
[http://dx.doi.org/10.1124/jpet.115.226993] [PMID:  26311812] 
[74]
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol  2007; 2(12): 751-60.
[http://dx.doi.org/10.1038/nnano.2007.387] [PMID:  18654426] 
[75]
Sofias AM, Dunne M, Storm G, Allen C. The battle of “nano” paclitaxel. Adv Drug Deliv Rev  2017; 122: 20-30.
[http://dx.doi.org/10.1016/j.addr.2017.02.003] [PMID:  28257998] 
[76]
Yang C, Wang J, Chen D, et al. Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice. Int J Nanomedicine  2013; 8: 1439-49.
[PMID:  23610522] 
[77]
Sahakyan N, Haddad A, Richardson S, et al. Personalized nanoparticles for cancer therapy: A call for greater precision. Anticancer Agents Med Chem  2017; 17(8): 1033-9.
[http://dx.doi.org/10.2174/1871520617666170102150730] 
[78]
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood  1999; 93(5): 1658-67.
[http://dx.doi.org/10.1182/blood.V93.5.1658] [PMID:  10029595] 
[79]
Ashley JD, Stefanick JF, Schroeder VA, et al. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J Control Release  2014; 196: 113-21.
[http://dx.doi.org/10.1016/j.jconrel.2014.10.005] [PMID:  25312543] 
[80]
Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clin Cancer Res  2012; 18(2): 342-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-2212] [PMID:  22065077] 
[81]
Ozaki S, Tanaka O, Fujii S, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol  2007; 86(2): 180-5.
[http://dx.doi.org/10.1532/IJH97.07030] [PMID:  17875535] 
[82]
Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: A meta-analysis. Biosci Rep  2017; 37(4): BSR20170304.
[http://dx.doi.org/10.1042/BSR20170304] [PMID:  28706008] 
[83]
Zhang S, Gangal G. Uludağ H. ‘Magic bullets’ for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem Soc Rev  2007; 36(3): 507-31.
[http://dx.doi.org/10.1039/B512310K] [PMID:  17325789] 
[84]
Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood  2012; 119(6): 1468-78.
[http://dx.doi.org/10.1182/blood-2011-07-368050] [PMID:  22096244] 
[85]
Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood  2009; 113(18): 4341-51.
[http://dx.doi.org/10.1182/blood-2008-10-186668] [PMID:  19139079] 
[86]
Azab AK, Azab F, Blotta S, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood  2009; 114(3): 619-29.
[http://dx.doi.org/10.1182/blood-2009-01-199281] [PMID:  19443661] 
[87]
Federico C, Alhallak K, Sun J, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun  2020; 11(1): 6037.
[http://dx.doi.org/10.1038/s41467-020-19932-1] [PMID:  33247158] 
[88]
Yadav A, Murthy M, Shete A, Sakhare S. Stability aspects of liposomes. Indian J Pharm Educ Res  2011; 45(4): 402-13.

[89]
Briuglia ML, Rotella C, McFarlane A, Lamprou DA. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res  2015; 5(3): 231-42.
[http://dx.doi.org/10.1007/s13346-015-0220-8] [PMID:  25787731] 
[90]
Demel RA, De Kruyff B. The function of sterols in membranes. Biochimica et Biophysica Acta (BBA)-. Reviews on Biomembranes  1976; 457(2): 109-32.

[91]
Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta  1973; 311(3): 330-48.
[http://dx.doi.org/10.1016/0005-2736(73)90314-3] [PMID:  4729825] 
[92]
Mohammed AR, Weston N, Coombes AGA, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int J Pharm  2004; 285(1-2): 23-34.
[http://dx.doi.org/10.1016/j.ijpharm.2004.07.010] [PMID:  15488676] 
[93]
Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol  2008; 87(3): 223-8.
[http://dx.doi.org/10.1007/s00277-007-0375-6] [PMID:  17874102] 
[94]
Fra AM, Williamson E, Simons K, Parton RG. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci USA  1995; 92(19): 8655-9.
[http://dx.doi.org/10.1073/pnas.92.19.8655] [PMID:  7567992] 
[95]
Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev  2004; 84(4): 1341-79.
[http://dx.doi.org/10.1152/physrev.00046.2003] [PMID:  15383654] 
[96]
Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol  2005; 288(3): C494-506.
[http://dx.doi.org/10.1152/ajpcell.00458.2004] [PMID:  15692148] 
[97]
Chatterjee M, Hönemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood  2002; 100(9): 3311-8.
[http://dx.doi.org/10.1182/blood-2002-01-0102] [PMID:  12384432] 
[98]
Podar K, Tai Y-T, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem  2003; 278(8): 5794-801.
[http://dx.doi.org/10.1074/jbc.M208636200] [PMID:  12482878] 
[99]
Yin W, Li Z, Zhang W. Modulation of bone and marrow niche by cholesterol. Nutrients  2019; 11(6): 1394.
[http://dx.doi.org/10.3390/nu11061394] [PMID:  31234305] 
[100]
Vladimirova SG, Tarasova LN. Lipid metabolism in patients with hematologic cancers. Ter Arkh  2016; 88(3): 116-20.
[http://dx.doi.org/10.17116/terarkh2015883116-120] [PMID:  28635913] 
Rights & Permissions Print Cite
Article Metrics
6
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574885517666220426092902	Print ISSN 1574-8855
Publisher Name Bentham Science Publisher	Online ISSN 2212-3903
Current Drug Therapy

Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target-specific Nanotherapies in Disease Models

Abstract Play Pause

Graphical Abstract

Abstract
